Health Journal Online

Category: Diseases & Conditions

UCLA Wins $3.9 Million to Test Drugs That Might Make Melanoma Immunotherapy Work for More Patients

Immune checkpoint inhibitors transformed melanoma treatment. They also leave a large share of patients behind, and figuring out what to do for those patients is the central unsolved problem in the field.

UCLA researchers have received a five-year, $3.9 million grant from the National Cancer Institute to work on it. The award goes to Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, according to UCLA Health. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy.

This is funding for research, not a result. Nothing has been shown to help any patient, and the work described is preclinical.

The Grant Is About Fixing Non-Response, Not Explaining It

A distinction worth drawing precisely, because it changes what to expect from this work.

The project is not primarily a study of why some patients respond, and others do not. It is drug development aimed at overcoming barriers already identified. Using a drug screening platform developed in the Puig-Saus laboratory to test thousands of compounds, the team identified two candidates, and the two work by different routes.

One appears to strengthen the interaction between T cells and cancer cells, helping the immune system mount a more effective attack. The other makes tumor cells more susceptible to destruction by T cells without directly altering the immune cells themselves. That second approach is notable because it sidesteps the problem of a patient’s T cells being exhausted or scarce.

The funding will support testing whether those compounds boost the effectiveness of existing immunotherapies in preclinical melanoma models, investigating how the drugs work, and evaluating their potential to be used safely. Puig-Saus has said that because the compounds are designed to work alongside existing immunotherapies, the approach could potentially apply across many cancer types.

Why So Many Patients Do Not Respond

The underlying problem is worth explaining, because it is what any approach has to solve.

Checkpoint inhibitors work by releasing the brakes on T cells so they can attack tumors. That only helps if T cells can find the tumor in the first place. Two failure modes dominate.

The first is recognition. T cells often struggle to identify cancer cells, particularly when tumors reduce the display of the surface molecules that mark a cell as abnormal. A tumor the immune system cannot see is not helped by removing a brake.

The second is evasion. Tumors evolve under immune pressure. They can lose the specific proteins T cells were targeting, recruit suppressive cells, or create a local environment that exhausts T cells. Tumors described as cold have few infiltrating T cells to begin with.

The scale of the gap is substantial. UCLA has previously reported that 40 percent of patients with melanoma do not respond to checkpoint blockade, with response especially poor in rarer forms including acral melanoma on the palms and soles, uveal melanoma in the eye, and mucosal melanoma.

The Screening Platform Is the Method Worth Noting

How the two candidate compounds were found says something about where cancer drug discovery has moved.

Rather than starting from a hypothesis about a single molecule, the laboratory built a screening platform capable of testing thousands of compounds for effects on the interaction between T cells and cancer cells. That approach asks which compounds change the behavior of the system, then works backward to understand why.

The advantage is that it can surface candidates nobody would have predicted from existing biology. The trade-off is that a compound identified this way arrives without a fully worked-out mechanism, which is precisely why part of the grant is devoted to investigating how the drugs work rather than only whether they work.

That mechanistic question is not academic. Understanding how a compound acts is what allows researchers to predict side effects, identify which patients might benefit, and design sensible combinations with existing immunotherapies.

The Timeline for Anything Reaching Patients

Preclinical grants are frequently reported in ways that imply proximity to treatment, and the arithmetic does not support that.

Five years of preclinical work would be followed, if results justify it, by formal toxicology studies, manufacturing under regulated conditions, and an investigational new drug application before a first human trial. That first trial would test safety and dosing rather than benefit. Efficacy testing would follow.

Most compounds entering this pipeline do not reach patients. That is not pessimism about this particular project; it is the base rate, and it is why the honest framing is that federal funding has been committed to a promising question.

What patients with melanoma can act on is different. Checkpoint inhibitors, targeted therapies for BRAF-mutant disease, and tumor-infiltrating lymphocyte therapy are all available now depending on tumor characteristics and prior treatment. Molecular testing of the tumor determines which apply.

For patients whose disease has progressed on checkpoint inhibitors, clinical trials are frequently the most substantive option, and enrollment is concentrated at academic and NCI-designated cancer centers. The same laboratory is separately advancing an experimental CAR T cell therapy for melanoma toward a trial, which is the kind of option worth asking an oncologist about directly.

Melanoma prevention and early detection remain the most effective interventions available. Anyone noticing a mole that changes in size, shape, or color, has an irregular border or uneven color, or looks different from other moles should have it examined. Early-stage melanoma is frequently curable with surgery alone.

This article is general information and is not medical advice.

Frequently Asked Questions

What was funded? A five-year, $3.9 million National Cancer Institute grant to Cristina Puig-Saus at UCLA.

What will the money support? Preclinical testing of two compounds identified through a drug screening platform, aimed at boosting existing immunotherapies in melanoma models.

How do the two compounds differ? One strengthens the interaction between T cells and cancer cells. The other makes tumor cells more vulnerable to T cells without altering the immune cells.

Why do checkpoint inhibitors fail in some patients? T cells often cannot recognize cancer cells, and tumors evolve to evade immune attack. UCLA has reported that 40 percent of melanoma patients do not respond.

Has anything been shown to work? No. This is funding for research. No patient benefit has been demonstrated.

When could this reach patients? Not for many years, if at all. Preclinical work precedes toxicology, manufacturing, and first-in-human safety trials.

What can melanoma patients do now? Ask about molecular testing, currently approved options, and open clinical trials, particularly at NCI-designated centers.

Source link

August 7, 2026
A Smuggling Prosecution Over Inactivated Mpox Samples Has Scientists Warning About Outbreak Preparedness

Two National Institutes of Health virologists have pleaded not guilty to charges of conspiring to smuggle mpox samples into the United States, in a case that a dozen scientists interviewed by KFF Health News say has less to do with public danger than with the paperwork that governs how American laboratories study overseas outbreaks.

The samples were inactivated. The FBI’s own testing confirmed it, and one of the charged researchers helped develop the inactivation technique. That detail sits at the center of why the prosecution has unsettled the infectious disease research community.

The practical stakes for households are indirect but real. The pipeline that produces diagnostic tests for emerging viruses runs through exactly this kind of specimen transfer, and researchers say the case is already changing how willing they are to participate.

The Case as Charged

Vincent Munster, chief of the virus ecology section at NIH’s Rocky Mountain Laboratories in Hamilton, Montana, and Claude Kwe, a research fellow working under him, were stopped at Detroit Metropolitan Airport on January 25, arriving on a flight from Paris after nine days in the Republic of the Congo.

They were arrested on June 2, when a criminal complaint was unsealed in federal court in Detroit charging conspiracy to smuggle mpox into the United States and lying to border agents. According to the complaint, the two told customs officials that the tubes in their luggage held diagnostic reagents. Each faces a maximum of five years.

The Justice Department’s announcement said FBI testing had confirmed the viruses were inactivated but that the scientists jeopardized Americans’ safety. Jerome Gorgon, U.S. attorney for the Eastern District of Michigan, said the researchers had smuggled viral pathogens on a packed commercial airplane from an outbreak.

Federal code requires researchers to register and certify inactivated viruses. The complaint states the pair lacked appropriate documents. Both scientists have been suspended and barred from the laboratory campus during an internal investigation, as MedicalDaily reported. Kwe’s federal community defender has said only that his client is presumed innocent and that comment should await further proceedings.

The Reason Laboratories Bring Samples Home

Studying an outbreak from a distance has limits. Developing a diagnostic test that reliably detects a circulating strain requires working with material from that strain, and validating a laboratory method requires the same.

Several scientists told KFF Health News that the specimens Munster and Kwe carried were most likely intended for exactly the diagnostic development purpose stated to customs officers. Tracking viral evolution, evaluating whether existing tests still detect new variants, and assessing whether vaccines and treatments remain effective all depend on access to current specimens from where transmission is occurring.

This work is regulated rather than freewheeling. Import permits, select agent rules, inactivation certification, institutional biosafety review and hazardous materials shipping requirements all apply, and researchers typically coordinate them weeks in advance with an institution’s biosafety office. The allegation here is a failure to satisfy those requirements, not an allegation that the material itself was dangerous.

A Pattern Researchers Say They Recognize

The case follows a series of prosecutions involving biological material carried or shipped by scientists, several brought by the same US attorney’s office in the Eastern District of Michigan. Earlier cases involved Chinese nationals at a University of Michigan laboratory and a Russian-born Harvard researcher stopped with frog embryos.

Reporting by KFF Health News, published through CNN, found that a dozen scientists interviewed characterized the arrests as part of a broader campaign, arguing that any errors involved were procedural and posed no threat to the public.

The reaction inside the field is about credibility as much as law. Kim Hasenkrug, an NIH scientist emeritus who worked at Rocky Mountain Laboratories for 31 years, said the episode gives ammunition to people trying to stop this valuable research and sows distrust even among people who had trusted the laboratory in the past.

NIH has said it activated established notification procedures and is cooperating with law enforcement, while declining further comment.

The Downstream Effect on Detection Speed

The concern researchers raise is not about this case’s outcome. It is about what other scientists conclude from watching it.

If participating in an international outbreak response carries perceived legal exposure, fewer researchers volunteer, fewer specimens move, and the interval between a new pathogen appearing somewhere and a validated test existing everywhere gets longer. That interval is what determines how early an outbreak is caught in a US emergency department.

Funding is compounding the problem. Scientists told KFF Health News that cuts to US foreign aid and research funding have left tens of millions of dollars in gaps in the response to spreading Ebola and mpox outbreaks.

None of this is measurable yet, and it would be overstating the evidence to claim detection has already slowed. What can be said is that the researchers doing this work say the deterrent is real, and that no formal change to import rules or NIH collaboration policy has been announced.

For readers, mpox risk in the United States remains concentrated in specific exposure contexts rather than general community spread, and CDC guidance on vaccination for people at higher risk has not changed as a result of this case. The next developments to watch are further court proceedings, reported from Detroit, and any policy guidance from NIH or HHS on international specimen transport.

Frequently Asked Questions

Were the samples dangerous? FBI testing confirmed the mpox virus in the vials was inactivated. One of the charged researchers helped develop the inactivation method.

What are the charges? Conspiracy to smuggle and lying to federal agents. Each carries a maximum of five years. Both defendants pleaded not guilty.

Why do researchers import virus samples? To develop and validate diagnostic tests, track viral evolution and assess whether existing vaccines and treatments remain effective against circulating strains.

Is that legal? Yes, with permits, inactivation certification, and proper declaration. The allegation is that those requirements were not met.

Does this affect my mpox risk? No. The case does not change transmission risk or CDC vaccination guidance for people at higher exposure risk.

Has anything about research rules changed? No formal change to import requirements or NIH collaboration policy has been announced. Both scientists are suspended pending an internal investigation.

What happens next? The case proceeds through federal court in the Eastern District of Michigan.

Source link

August 6, 2026
Outdoor Crews Absorb the Highest Smoke Doses, and Respirator Fit Decides How Much Protection They Get

While households in Spokane County are being told to close windows and run filtration, an orchard crew and a framing crew are working outside in the same air. They will absorb a dose of fine particulate matter that no amount of household advice addresses, because the advice assumes you can go indoors.

The difference is not small, and it comes from two multipliers stacked on each other.

The first is time. A resident who makes two short trips outside might accumulate 30 minutes of exposure. A crew works eight to ten hours in it. The second is breathing rate. Physical labor raises minute ventilation substantially, meaning a worker moves several times more air through their lungs per hour than someone at rest. Every additional liter carries the same particle concentration.

Multiply those together and an outdoor worker on a bad smoke day can inhale many times more PM2.5 than a sedentary adult in the same ZIP code. That is why state health officials count outdoor workers among the groups most at risk from smoke, and why Washington wrote a rule specifically for them.

The State Rule Is A Ladder, Not A Switch

Washington is one of only a handful of states with an enforceable wildfire smoke standard. There is no federal OSHA standard for wildfire smoke, which means a crew’s protections depend heavily on which side of a state line they are working on.

Under chapter 296-820 WAC, employer obligations escalate at defined PM2.5 concentrations rather than turning on at a single trigger. The rule tracks the hourly PM2.5 average in micrograms per cubic meter, with corresponding AQI values.

At 20.5 to 35.4 micrograms, roughly AQI 72 to 100, employers must notify workers of conditions, ensure only trained employees work outdoors, consider exposure controls, and are encouraged to provide N95 respirators at no cost on request.

At 35.5 to 250.4 micrograms, roughly AQI 101 to 350, employers must implement exposure controls and make N95 respirators available at no cost for voluntary use. This is the band that covers most smoke days.

At 250.5 to 500.3 micrograms, roughly AQI 351 to 848, employers must distribute N95S directly to each exposed employee rather than simply making a supply available, must encourage their use, and must ensure access to clean air.

From 500.4 micrograms up, employers must implement a complete required-use respiratory protection program including fit testing, medical evaluations, and clean-shaven use, unless exposure totals 15 minutes or less over 24 hours. At 555 micrograms and above, the required respirator must carry an assigned protection factor of 25 or more, which means something more protective than a filtering facepiece.

Oregon operates a separate rule with different trigger points. A contractor whose crews cross the Columbia River cannot run one plan written to one state’s numbers.

Voluntary Use and Required Use Diverge on Fit

This is the part most often misunderstood, and it determines how much a respirator actually accomplishes.

An N95 works by forming a seal against the face so air passes through the filter media rather than around the edges. A fit test verifies that a specific model and size seals on a specific person. Under the rule, a full respiratory protection program with fit testing and medical evaluation applies when PM2.5 reaches 500.4 micrograms or when the employer chooses to require respirator use. Below that, use is voluntary and fit testing is not required.

That means on the vast majority of smoke days, workers are wearing respirators that have never been verified to seal on their faces. The rule acknowledges this and tells workers that even without a fit test, they can take steps to improve the seal.

Those steps are practical. Both straps go around the head, not looped over the ears, with one above and one below the ears. The metal nose clip is molded to the bridge of the nose with two hands rather than pinched with one. A seal check follows: cover the respirator, exhale gently, and feel for air escaping at the edges or fogging on glasses.

Facial hair is the variable nobody enjoys discussing. Stubble and beards break the seal along the jaw and cheeks, and no adjustment fixes it. Where respirator use is required, workers must be clean-shaven. There is one exception worth knowing: loose-fitting powered air-purifying respirators do not depend on a facial seal, which makes them the practical option for workers who cannot or will not shave.

Respirators also increase breathing resistance. Anyone with a heart or lung condition should ask a clinician whether wearing one during physical work is appropriate, since the added effort places its own demand on the cardiovascular system.

Dust Masks and KN95s Are Not Substitutes

Washington’s Labor and Industries guidance is unusually blunt here, and the distinction matters because job sites are full of masks that do nothing for smoke.

Bandanas, scarves, facemasks and t-shirts worn over the nose and mouth “do not provide any protection against wildfire smoke,” according to L&I, and facemasks and dust masks not certified by NIOSH do not adequately protect workers.

KN95s are the trickier case because they look nearly identical to N95s. L&I states that they are not NIOSH-certified and “do not provide protection from wildfire smoke.” A genuine N95 carries NIOSH approval markings printed on the respirator itself. The agency’s position is that a NIOSH-approved N95 is the minimum protection from wildfire smoke.

Questions A Crew Can Ask This Week

Conditions make this immediate. The Spokane Regional Clean Air Agency has an air quality alert in effect with widespread smoke from the local Spokane Complex fires and regional fires, and forecast air quality ranging from Unhealthy to Very Unhealthy as a ridge of high pressure reduces ventilation. Those levels put worksites in the band where N95s must be made available, and potentially into the band where they must be handed to each worker.

Workers in affected areas can ask their employer three specific things without needing to cite the rule by number.

What PM2.5 or AQI figure is the site using, and where does it come from? Employers may use a direct-reading particulate sensor operated under the conditions the rule sets, or rely on published government data. Knowing the source tells a worker whether obligations are being tracked in real time or guessed at.

Are N95S available on site right now, at no cost, and in more than one size? Size availability is the difference between a respirator that seals and one that does not.

Has anyone received wildfire smoke training this season? Training is a prerequisite for outdoor work under the rule at the lowest threshold, and employers must also notify workers each time conditions cross a threshold.

Workers should watch for coughing, chest tightness, wheezing, headache, dizziness, and unusual fatigue, and report symptoms rather than working through them. Difficulty breathing, chest pain, or confusion require immediate medical attention. Workers with asthma or COPD should keep rescue medication on their person rather than in a vehicle. This is general information and is not medical advice.

Concerns about employer non-compliance can be raised with Washington L&I, and the rule bars employers from retaliating against workers who raise safety concerns or report symptoms. Agricultural workers are covered by a parallel rule and can request materials in a language they understand.

MedicalDaily will report changes in state occupational smoke standards and any federal rulemaking on wildfire smoke exposure.

Frequently Asked Questions

Why do outdoor workers face higher exposure? They spend full shifts in smoke and breathe far more air per hour because of physical exertion, so cumulative dose is much higher than for most residents.

When must a Washington employer provide N95s? At PM2.5 of 35.5 micrograms or more, roughly AQI 101, employers must make them available at no cost for voluntary use. At 250.5 micrograms they must be distributed directly to each exposed worker.

Do workers get a fit test? Not for voluntary use. Fit testing, medical evaluation, and clean-shaven use apply when respirator use is required, which begins at 500.4 micrograms or when an employer chooses to require it.

Does a KN95 work for smoke? Washington L&I says no. KN95s are not NIOSH-certified. Look for NIOSH approval markings printed on the respirator.

What about a beard? Facial hair breaks the seal. Loose-fitting powered air-purifying respirators are the exception because they do not depend on a facial seal.

Is there a federal rule? No federal OSHA wildfire smoke standard exists. Protections depend on state rules, and Washington and Oregon use different thresholds.

What symptoms should prompt stopping work? Difficulty breathing, chest pain, dizziness or confusion require immediate medical attention. Persistent cough or wheeze should be reported rather than worked through.

Source link

August 5, 2026
Senators Demand Records from Three Medicare Advantage Insurers on How Post-Hospital Care Gets Denied

Two senators have demanded that the three largest Medicare Advantage insurers turn over internal records showing exactly how they decide whether to pay for care after a hospital stay, including any use of algorithms or software to judge medical necessity.

The July 14 letters from Sen. Richard Blumenthal of Connecticut and Sen. Josh Hawley of Missouri went to UnitedHealthcare, Humana and CVS Health, and covered decisions on skilled nursing facilities, inpatient rehabilitation facilities and long-term acute care hospitals dating back to January 2023. The insurers were given until July 28 to respond.

The households at stake are specific. These are families deciding, often within 48 hours of a hospital discharge, whether a parent goes to a rehabilitation facility or comes home. A denial at that moment reshapes the decision, and federal auditors have found that most of those denials do not survive an appeal.

The Scope of What Is Being Asked

The senators, who sit on the Senate Permanent Subcommittee on Investigations, requested records on each company’s process for authorizing or covering post-acute care, an inventory of the predictive technologies each uses, and confirmation of whether it remains company policy that a final denial cannot be made by artificial intelligence.

That last question is the sharpest one. It asks the companies to restate a commitment on the record rather than in a press release.

In their letter to Humana, the senators wrote that without comprehensive reporting requirements, Medicare Advantage insurers “are able to hide the full extent of denials of care.” The subcommittee’s announcement framed the request as testing claims the companies have made since a 2024 subcommittee report that they are reducing prior authorization burdens.

What Federal Auditors Found First

The letters follow two reports published on June 8 by the Department of Health and Human Services Office of Inspector General, which examined prior authorization data from 19 Medicare Advantage insurers using June 2024 records.

One report found that UnitedHealthcare, Humana and CVS denied admission requests to long-term acute care hospitals and inpatient rehabilitation facilities at higher rates than their peers. The letter to UnitedHealthcare cited a finding that the company denied 66 percent of inpatient rehabilitation facility admission requests, against an average of 41 percent across 16 smaller insurers.

The second report found the three insurers collectively denied 12 percent of skilled nursing facility requests. Humana denied 13.5 percent of all such requests. Nearly all appealed denials were later overturned. Both reports flagged the role of NaviHealth, a utilization management vendor owned by UnitedHealth’s Optum unit.

The cost context is part of why insurers scrutinize these admissions. Medicare’s average cost for a post-hospital rehabilitation stay ranged from roughly $16,000 to $49,000 in 2023, and insurers argue that variation in price and quality among facilities justifies review. Both OIG reports are posted publicly.

That overturn rate is the number that matters most to families. A denial that gets reversed on appeal still delayed care while the appeal ran, and comparatively few patients file one.

The Limits of a Congressional Records Demand

A letter from a subcommittee is not a subpoena, not a regulation, and not a lawsuit. It carries no automatic penalty, and companies routinely respond with material designated confidential.

What an inquiry of this kind can produce is a public record. The subcommittee’s October 2024 report was built from more than 280,000 pages of internal documents obtained the same way, and it established the denial-rate comparisons that federal auditors later echoed. Documents gathered now could support a future public report, a hearing, or legislation.

What it cannot do is reverse anyone’s denial. No individual patient’s coverage decision changes because of this inquiry, and there is no timeline by which the subcommittee must publish anything.

Separate tracks are moving. The House Ways and Means Committee unanimously approved the Improving Seniors’ Timely Access to Care Act of 2026, which would standardize electronic prior authorization in Medicare Advantage and require plans to report denial rates to the federal government. The American Medical Association said the vote reflects recognition that prior authorization “too often stands between patients and their physicians.” Federal interoperability rules requiring faster prior authorization decisions also phase in through 2027.

The companies have not been found to have violated any law in connection with this inquiry, and the questions in the letters are allegations and requests rather than findings.

What Families Facing a Discharge Can Do Now

None of this changes the practical playbook for a household in the middle of a discharge decision, and that playbook is worth knowing before it is needed.

Ask the hospital case manager to put the recommended level of post-acute care in writing, with the clinical reasoning attached. That document becomes the backbone of an appeal. Request the denial in writing if one is issued, including the specific coverage criterion cited. File an appeal, and ask about an expedited appeal if the patient is still hospitalized or a delay would jeopardize recovery. Federal auditors found most appealed post-acute denials get overturned, which makes the appeal the single highest-value action available.

Families can also contact their State Health Insurance Assistance Program for free counseling, and can call 1-800-MEDICARE to report a problem.

Nobody should refuse recommended medical care because of a coverage dispute. Decisions about where a patient recovers belong with the clinical team, with the coverage question handled in parallel.

The subcommittee has not announced whether it will publish the material it receives or hold a hearing. MedicalDaily will report on any subcommittee findings, further OIG audits, or floor action on the prior authorization legislation.

Frequently Asked Questions

What did the senators actually ask for? Records on how each insurer decides post-acute care coverage, an inventory of predictive technologies used, and confirmation of whether final denials can be made by artificial intelligence.

Which insurers received the letters? UnitedHealthcare, Humana and CVS Health, the three largest Medicare Advantage organizations.

What did federal auditors find? Two June reports found the three insurers denied post-acute admission requests at higher rates than peers, and that nearly all appealed skilled nursing denials were later overturned.

Does this change anyone’s coverage? No. A congressional records request has no effect on an individual coverage decision.

What should a family do if post-hospital care is denied? Request the denial in writing with the criterion cited, ask the hospital case manager for written clinical reasoning, and file an appeal, including an expedited appeal if a delay would harm recovery.

Are the insurers accused of breaking the law? No. The letters request information and cite audit findings. No legal violation has been established in connection with this inquiry.

Is legislation moving? The House Ways and Means Committee approved the Improving Seniors’ Timely Access to Care Act of 2026, which would standardize electronic prior authorization and require denial-rate reporting. It has not become law.

Source link

August 4, 2026
Patients Waiting Out Drug Shortages Have a Stake in an Obscure FDA Registration Proposal

A quiet FDA rulemaking would require more foreign drug plants to register. Better upstream visibility is how shortages get caught earlier.

Source link

August 3, 2026
Voters Put Preventing Maternal Deaths at the Top of Their Health Agenda, and Federal Data Show 649 Women Died in 2024

Asked to name their top two priorities for policymakers on maternal health, registered voters put preventing maternal deaths first, at 32 percent, ahead of early care and intervention during pregnancy at 22 percent.

The survey, released July 30 by the advocacy organization Healthy Moms, Healthy Babies America and conducted by KAConsulting, polled 1,001 registered voters nationwide between July 12 and 16, with a margin of error of plus or minus 3 percentage points. Because it was commissioned by an organization advocating for maternal health policy, its framing and question wording reflect that purpose, and the findings should be read as advocacy polling rather than independent research.

What makes the result worth reporting is that federal surveillance data exist to check it against. Opinion tells you what people want addressed. Vital statistics tell you what is actually happening.

The Federal Numbers Behind the Priority

The National Center for Health Statistics published final 2024 maternal mortality data in March. In 2024, 649 women died from maternal causes in the United States, compared with 669 the year before. The rate was 17.9 deaths per 100,000 live births, which NCHS described as not significantly lower than the 2023 rate of 18.6.

That word matters. The apparent decline is within the range of statistical noise. NCHS notes that maternal mortality rates fluctuate year to year because the absolute number of events is relatively small, and because accuracy in recording maternal deaths on death certificates remains an ongoing data-quality problem the agency is still working on.

The disparities are larger than the year-to-year movement. For Black non-Hispanic women, the 2024 rate was 44.8 deaths per 100,000 live births, three times the rate of 14.2 for white non-Hispanic women. Changes from 2023 to 2024 across racial groups were not statistically significant.

Age is the other major gradient. Women 40 and older had a maternal mortality rate of 62.3 per 100,000, nearly five times the rate of 13.7 among women younger than 25. Women aged 25 to 39 fell at 16.5.

Two Different Federal Counts, and Only One Measures Preventability

Readers encountering different maternal death figures are usually seeing two separate systems, and the distinction matters for the question the poll asked.

The NCHS figures above count maternal deaths, defined internationally as deaths during pregnancy or within 42 days of the end of pregnancy from causes related to pregnancy. That is a vital statistics count drawn from death certificates.

A second system, Maternal Mortality Review Committees, examines pregnancy-related deaths, which include deaths up to one full year after the end of pregnancy. These committees are multidisciplinary panels that review individual cases in detail, and they are the only source that assigns preventability determinations and issues recommendations. CDC funds this work through the ERASE MM program, which supports committees across most states and territories.

That second system is what the poll’s language about “preventing” maternal deaths actually maps onto. A vital statistics count establishes how many women died. A review committee establishes whether the death could have been avoided and what would have changed the outcome. Congress reauthorized the Preventing Maternal Deaths Act in February 2026 through 2030, with $113.5 million appropriated to the account funding this work.

Where the Poll and the Data Line Up

Several of the specific policies voters endorsed correspond to problems the surveillance data identify.

Eighty-eight percent of respondents supported expanding specialty care and telehealth for women with high-risk pregnancies in rural and underserved communities. Access to risk-appropriate care is a recurring theme in review committee findings, and rural obstetric unit closures have lengthened travel distances for delivery in many states.

Eighty-seven percent supported a whole-health approach including maternal mental health, nutrition, and chronic disease management. That aligns with the extended one-year window review committees use, since deaths in the later postpartum period frequently involve mental health conditions, substance use, and cardiovascular disease rather than delivery complications.

Across 15 policy proposals tested, 13 drew support from at least 80 percent of respondents, all 15 drew at least 72 percent, and 79 percent said they would be more likely to vote for a candidate supporting them. Fifty-five percent held an unfavorable view of the U.S. health care system overall, and 51 percent viewed it unfavorably specifically on care for women.

One figure in the poll should be handled carefully. Seventy-two percent said they were more likely to support reforms after being told maternal mortality and morbidity cost the economy $165 billion in 2020. Questions that present a fact before asking for a response measure persuasion, not baseline opinion, and should not be reported as if they measured the latter.

What Patients and Families Can Do with This

Nothing in polling changes an individual’s risk. What does change outcomes is recognizing warning signs and being heard when reporting them.

CDC’s Hear Her campaign identifies urgent maternal warning signs that warrant immediate care during pregnancy and for a full year afterward. They include severe headache that will not go away, changes in vision, trouble breathing, chest pain or a racing heart, severe belly pain, a fever of 100.4 degrees or higher, extreme swelling of hands or face, thoughts of harming oneself or the baby, and heavy bleeding.

The one-year window is the part most often missed. Postpartum visits frequently stop at six weeks, while a substantial share of pregnancy-related deaths occur later. Anyone who gave birth within the past year and develops these symptoms should say so explicitly when seeking care, because clinicians who do not know about a recent pregnancy may not consider pregnancy-related causes.

Practical steps include identifying the nearest hospital with obstetric capability before delivery, particularly in rural areas, and asking about postpartum Medicaid coverage, which most states have extended to 12 months. Patients whose symptoms are dismissed can ask for the concern to be documented in the chart, request a second opinion, or contact the hospital’s patient advocate.

What happens next is a data question. NCHS publishes provisional maternal mortality estimates on a rolling basis and final annual figures with roughly a 15-month lag, meaning 2025 final data are not yet available. Whether the flat trend of the past two years turns into a genuine decline will not be answerable for at least another year.

Frequently Asked Questions

What did the poll find? Registered voters named preventing maternal deaths their top maternal health priority for policymakers at 32 percent, followed by early care and intervention during pregnancy at 22 percent.

Who conducted it? KAConsulting for Healthy Moms, Healthy Babies America, an advocacy organization. It surveyed 1,001 registered voters July 12 to 16, 2026, with a margin of error of 3 percentage points.

How many women die from maternal causes? Federal data recorded 649 maternal deaths in 2024, a rate of 17.9 per 100,000 live births, which NCHS said was not significantly different from 2023.

How large are the racial disparities? Black non-Hispanic women had a rate of 44.8 deaths per 100,000 live births in 2024, three times the rate of 14.2 among white non-Hispanic women.

Why do different maternal death numbers circulate? Vital statistics count deaths within 42 days of pregnancy. Maternal Mortality Review Committees examine pregnancy-related deaths up to one year afterward and assess preventability.

What warning signs require immediate care? Severe persistent headache, vision changes, trouble breathing, chest pain, severe belly pain, fever of 100.4 or higher, extreme swelling, heavy bleeding, or thoughts of self-harm during pregnancy and for a year after.

How long does postpartum risk last? Up to a full year. Anyone who gave birth in the past 12 months should tell clinicians about the pregnancy when seeking care for new symptoms.

Source link

August 2, 2026
FTC Alleges a Telehealth Company Sent Users’ Health Conditions to Ad Platforms After Promising Discretion

Federal regulators have accused one of the largest direct-to-consumer telehealth companies of routing customers’ health conditions to advertising platforms while marketing itself on privacy.

The Federal Trade Commission, joined by Utah and by California through Los Angeles County Counsel, sued Hims and Hers Health on July 29 in federal court in San Francisco. The complaint alleges the company shared sensitive health information about medical conditions with third-party advertising platforms despite promising privacy, and separately alleges deceptive billing and cancellation practices.

None of this has been proven. The company disputes the allegations and says it will defend itself. A complaint is an accusation, and the court has made no findings.

The reason it matters to readers who have never used the platform is the category. The conditions named are the ones people specifically seek online care for because they do not want to discuss them in person.

What the Complaint Says Moved, and Where

The alleged mechanism is a tracking pixel, a small piece of code embedded in a web page that reports visitor activity back to a third party. Pixels are ordinary infrastructure across commercial websites. They become a health privacy question when the page being tracked reveals a medical condition.

According to the complaint as reported by TechCrunch, the company placed trackers supplied by Meta and Snap as well as Microsoft, Pinterest, Reddit, and X. The FTC also alleges the company uploaded lists of certain customers to advertising platforms, a separate practice from pixel tracking that matches known customer identities against platform user accounts.

The service lines named in reporting on the complaint include erectile dysfunction, premature ejaculation, hair loss, weight management, and mental health. The FTC’s contention is that the company advertised privacy and discretion for exactly these categories while the data pipeline ran the other direction.

Christopher Mufarrige, director of the FTC’s Bureau of Consumer Protection, said in the agency’s announcement that the complaint describes “consumers unknowingly locked into recurring subscriptions” alongside disclosure of private health information without consent.

The Billing Allegations Sit Alongside the Privacy Ones

The complaint pairs the data claims with allegations about money, which is unusual and is part of why the case is being watched.

Regulators allege the company advertised free consultations and displayed language indicating no payment was due at intake, then charged consumers and enrolled them in recurring subscriptions once a provider wrote a prescription, in some cases before any consultation had occurred. The complaint further alleges that cancellation was made difficult, leaving some customers paying for refills they did not want.

The cited legal authorities are the FTC Act and the Restore Online Shoppers’ Confidence Act, a 2010 statute governing online negative-option billing, which requires clear disclosure of terms, informed consent before charging, and a simple cancellation mechanism.

The company has responded firmly. In statements reported by BioPharma Dive and others, Hims and Hers called the claims baseless, said its privacy policy makes clear that users may choose how their data is used, and said it is confident in its position. It did not explicitly deny the specific factual allegations in the statements reported.

A Pattern the Agency Has Pursued Before

This is not a novel theory of enforcement. The FTC brought similar actions against GoodRx and BetterHelp in 2023, and against the telehealth startup Cerebral and the alcohol recovery provider Monument, in each case alleging that consumer health data reached advertising platforms through website technology.

The industry has responded to that pressure. Pixel deployment on hospital websites fell from about 98 percent in 2021 to roughly 30 percent in 2025, according to tracking data compiled by health marketing analytics firm Hedy and Hopp and reported by Bloomberg Law. That figure describes hospitals rather than direct-to-consumer telehealth, and should not be read as a measure of the latter.

One legal point is worth understanding because it surprises people. Most direct-to-consumer telehealth platforms operate in a space where HIPAA’s application is contested or limited, which is part of why the FTC rather than the HHS Office for Civil Rights is the agency bringing this case. Consumers frequently assume that anything involving a prescription is covered by federal medical privacy law. That assumption does not reliably hold for app-based commercial health services.

Steps for Anyone Who Has Used a Telehealth Platform

Nobody should stop needed treatment over a privacy dispute, and nothing here suggests any medication is unsafe. The relevant actions are about accounts and settings.

Check advertising controls on the platforms named. Meta, Google, and other services allow users to review and delete off-site activity that businesses have shared, and to limit how that data informs ad targeting. Those controls are typically found under account settings labeled activity, ad preferences, or data sharing.

Review recurring charges. Anyone enrolled in a telehealth subscription can check the current billing terms, the renewal date, and the cancellation process, and should document the date and method of any cancellation request. Consumers who believe they were charged without consent can dispute the charge with their card issuer and file a complaint with the FTC at ReportFraud.ftc.gov.

For future care, consider that browsing a condition-specific page on a commercial health site is not equivalent to a conversation in an exam room. Care delivered through a health system patient portal generally does sit under HIPAA. That is a meaningful difference for anyone who considers the condition itself sensitive.

Several things remain unresolved. The company has not filed its formal response. No court has ruled on any allegation. How many consumers were affected, what specific data elements moved, and what remedy regulators will seek are all matters for the litigation. MedicalDaily will report the company’s answer and any rulings.

Frequently Asked Questions

What did the FTC allege? That Hims and Hers shared consumers’ sensitive health information with third-party advertising platforms despite promising privacy, and separately deceived users about billing and cancellation.

Have the allegations been proven? No. The complaint was filed July 29, 2026, and no court has made findings. The company calls the claims baseless and says it will defend itself.

What is a tracking pixel? A small piece of code embedded in a web page that reports visitor activity to a third party. It becomes a health privacy issue when the page reveals a medical condition.

Which platforms are named? Reporting on the complaint identifies Meta and Snap along with Microsoft, Pinterest, Reddit, and X.

Does HIPAA cover telehealth apps? Not always. Many direct-to-consumer platforms operate outside or at the edges of HIPAA, which is why the FTC rather than HHS is bringing this action.

What can users do now? Review ad and data-sharing settings on the named platforms, check subscription billing terms and cancellation processes, and document any cancellation request.

Has the FTC done this before? Yes. It brought similar cases against GoodRx and BetterHelp in 2023, and against Cerebral and Monument.

Source link

August 1, 2026
Three Medical Device Categories Established in 2023 Are Now Officially Codified by the FDA

The FDA published three final orders on July 24 creating permanent regulatory categories for a test that estimates how fast chronic kidney disease will progress, a prescription app that delivers behavioral therapy for diabetes, and at-home COVID tests.

Each one reads like news. None of it happened this month.

All three orders codify classifications the agency already granted in mid 2023. The kidney test category became applicable on June 29, 2023, the COVID test category on June 6, 2023, and the diabetes app category on July 7, 2023. What changed last week is that the classifications now appear in the Code of Federal Regulations, at sections 862.1223, 866.3984, and 880.5735.

That distinction matters because nothing became newly available, newly covered by insurance, or newly recommended. The value in these documents is in the limitations FDA wrote into each category, which are more restrictive than the product names suggest.

What Each Category Actually Covers

The kidney category came from Renalytix AI’s KidneyIntelX.dkd, submitted in August 2020. FDA defines the generic type as an in vitro diagnostic that measures one or more analytes from human samples as an aid in assessing the risk of chronic kidney disease progression.

Then it draws hard boundaries. The regulation states the device is “not intended for diagnosis of any disease,” and separately that it is not intended for serial monitoring of kidney disease progression or for monitoring the effect of any therapeutic product. Labeling must carry those limits.

That is a narrower tool than most patients would assume. Standard kidney measures, estimated glomerular filtration rate and urine albumin, are used both to stage disease and to track it over time. A prognostic test in this category answers a different question once: how likely is this to get worse? It cannot tell a patient whether they are improving or whether a medication is working, and FDA explicitly forbids marketing it for that.

The diabetes category came from Better Therapeutics’ BT-001, submitted in September 2022. FDA defines it as a prescription software device providing digital behavioral therapy to aid diabetes management, and the agency’s own language is strikingly modest: the device is “intended to provide limited secondary benefit” to patients, and is “not intended to replace any primary treatment, such as diet/lifestyle changes or medication.“

Required labeling goes further. It must state the device is not for standalone therapy, not a substitute for prescribed therapy or medication, should not be used by people with unstable psychiatric disorders, and is not intended to treat any psychiatric disorder or symptoms.

Notably, among the risks FDA identified for this category is that treatment could result in anxiety, depressed mood, depression, stress, or suicidal ideation. That is an unusual hazard list for a diabetes product, and it explains the psychiatric exclusions.

The COVID category came from Cue Health’s Cue COVID-19 Molecular Test, submitted in May 2022, and covers at-home tests used by lay users without a health care provider.

The COVID Rule Is Where the Consumer Detail Sits

The at-home test regulation reads like a list of everything that goes wrong when people test themselves, converted into mandatory labeling.

Manufacturers must state that “positive results do not rule out co-infection with other respiratory pathogens,” and that a negative result does not exclude infection with something else. They must warn that the test is not a substitute for consulting a clinician and should not be used to determine treatment without provider supervision.

Two requirements deserve attention from anyone who keeps tests in a drawer. Labels must state that expired tests can produce incorrect results, and that accuracy depends on proper storage, which is a real issue for kits stored in hot cars or unheated garages. Labels must also state that false positives become more likely when community prevalence is low.

The variant requirement is the most interesting. Labeling must name the strain or variant that was dominant when performance was established, warn that accuracy may change as new viruses emerge, and advise that lab-based PCR testing should be considered when a new variant is suspected. Manufacturers must continuously monitor for genetic mutations and, if FDA asks, submit evaluations within 48 hours.

The rule also builds in emergency machinery. If a public health emergency involving SARS-CoV-2 is declared, manufacturers have 30 days from FDA notification to test their device against characterized samples and 60 days to publish results, continuing for three years.

Performance has a floor: clinical studies must show the lower bound of the two-sided 95% confidence interval for positive percent agreement exceeding 70%. That is a meaningful number for readers to hold, because it means a test in this category can legitimately miss a substantial share of infections.

What This Changes for Patients

Almost nothing, immediately, and that is the honest answer.

Class II with special controls means a device type avoids the automatic class III designation that would otherwise require premarket approval. The practical effect is on manufacturers rather than patients: once FDA classifies a device type this way, later companies can use the less burdensome 510(k) pathway instead of filing their own De Novo request. FDA said each action would “enhance patients’ access to beneficial innovation, in part by reducing regulatory burdens.“

Over time, that can mean more competitors and lower prices in a category. It is not a promise, and FDA has not exempted any of these three types from 510(k) review, so individual products still need their own authorization.

For patients, the useful takeaways are about expectations. Anyone offered a kidney progression test should understand it estimates risk once and is not a monitoring tool, and should ask what the result would change about their care. Anyone prescribed a diabetes therapy app should know FDA classified it as providing limited secondary benefit alongside, not instead of, medication and lifestyle change. Anyone using at-home COVID tests should check expiration dates, consider how the kit was stored, and treat a negative result during a new variant wave as less reliable than a PCR.

Nobody should start, stop, or change a medication, or skip a monitoring test, based on any of this.

One thing readers may notice: two of the three companies whose submissions created these categories have had well-publicized business difficulties since 2023, which is worth verifying before publication and which illustrates that a regulatory category outlasts the product that established it.

What Happens Next

Comments are closed on all three orders, which took effect on publication. The categories now function as predicates, so the next observable developments would be 510(k) clearances of similar devices, and any future FDA decision to exempt a type from premarket notification.

The bottom line: FDA codified three device categories on July 24, all of which were actually classified in 2023, covering a kidney progression test, a prescription diabetes therapy app, and at-home COVID tests. Patients considering any of the three should note the limits FDA wrote into each. The reasonable action is to ask what a given test or app would change about care. The central uncertainty is whether these categories attract competing products.

Frequently Asked Questions

What did FDA actually do? It published final orders adding three device categories to the Code of Federal Regulations. The underlying classifications were granted in June and July 2023.

Does this mean new tests are available? No. The devices that created these categories have been legally marketable since 2023. No new product launched.

What does the kidney test do? It estimates the risk that chronic kidney disease will progress. FDA states it is not for diagnosis, not for serial monitoring, and not for tracking whether a treatment is working.

Can a diabetes app replace my medication? No. FDA classified this device type as providing limited secondary benefit and requires labeling stating it is not a substitute for prescribed therapy or medication.

Who should not use a diabetes therapy app? FDA requires labeling stating it should not be used by people with unstable psychiatric disorders and is not intended to treat psychiatric conditions.

What changed for at-home COVID tests? Nothing you buy changed. The codified rule requires labeling about expiration, storage, variant limitations, co-infection, and when to seek PCR testing.

How accurate must an at-home COVID test be? Clinical studies must show the lower bound of the two-sided 95% confidence interval for positive percent agreement above 70%, meaning some infections will be missed.

Does class II mean FDA approved it? Class II devices generally require premarket notification, a 510(k), rather than premarket approval. FDA has not exempted any of these three types from that requirement.

Source link

July 31, 2026
Following Hailuo, Can Hyper-Realistic AI Videos Change How We Think, Feel, or Even What We Trust?

Chinese artificial intelligence company MiniMax has expanded its push into AI-assisted filmmaking with the launch of MiniMax Hub, an all-in-one creative platform powered by its Hailuo AI models. Introduced during the 2026 Shanghai International Film Festival, the platform brings together AI-generated images, video, audio, and editing tools within a single workspace, allowing users to move through much of the production process without switching between multiple applications. Users can describe a project using natural language or upload reference materials, while Hub’s AI agent helps coordinate different stages of production.

The launch comes as MiniMax continues to promote Hailuo as a platform for filmmakers and other creative professionals seeking to streamline content creation. At the same time, the company remains involved in an ongoing copyright lawsuit brought by Disney, Universal, and Warner Bros. Discovery, which allege that MiniMax used copyrighted works to train its AI system without authorization. MiniMax disputes those allegations, and the litigation remains ongoing.

Artificial or Real? MiniMax’s Hailuo Renews Questions About AI Videos and Mental Health

MiniMax has highlighted Hailuo and MiniMax Hub at film industry events, presenting the platform as a way to assist creators throughout the filmmaking process. According to the company, Hub integrates multiple AI capabilities into a single environment so users can generate visual assets, create videos from text prompts or reference images, produce audio, and edit projects without relying on several separate AI applications.

The platform is designed to generate a wide variety of creative content, including cinematic video clips, animated sequences, stylized visuals, and other multimedia assets for film and digital media production. MiniMax says the goal is to simplify production workflows by allowing an AI agent to coordinate multiple creative tasks within one interface.

The launch has also arrived amid broader debate surrounding generative AI. Supporters argue that integrated AI tools could help reduce production time and lower technical barriers for creators, while critics have raised concerns about copyright, artistic ownership, misinformation, and the growing realism of AI-generated media. Those discussions have intensified alongside legal challenges involving several AI companies, including MiniMax.

The Continued Studies on the Psychological Effects of Increasingly Realistic AI-Generated Media

As generative AI systems become capable of producing increasingly realistic images and videos, psychologists and digital media researchers are examining how synthetic content may influence mental well-being and public trust. While research is still emerging, existing evidence suggests that prolonged exposure to highly convincing AI-generated media may contribute to information overload and make it more difficult for people to distinguish authentic material from synthetic content.

Research has suggested that this growing uncertainty could contribute to cognitive overload and reduce confidence in digital information, particularly as AI-generated content becomes more common online. However, scientists have not established that AI-generated media alone directly causes these outcomes, and they continue to emphasize the need for long-term research to better understand its psychological effects.

Mental health experts have also raised concerns that highly convincing synthetic media, particularly when used to spread misinformation or create deceptive content, could contribute to anxiety, stress, or emotional manipulation in some situations. Current research suggests these are plausible concerns, but the evidence remains limited, and researchers continue to investigate how AI-generated media may affect emotional well-being over time. Many experts have also called for greater transparency and clear disclosure when AI-generated content is presented to the public.

Creativity In the Age of Generative AI

MiniMax Hub reflects the rapid evolution of generative AI from standalone image and video generators into integrated creative platforms capable of supporting larger portions of the production process. For filmmakers and other creative professionals, these tools may offer new ways to speed up production and experiment with visual storytelling.

At the same time, the technology has renewed discussion about copyright, authenticity, transparency, and public trust in digital media. As AI-generated content becomes increasingly difficult to distinguish from real footage, ongoing research and thoughtful safeguards will be important to understanding both the opportunities and the potential risks associated with this technology.

Many questions remain unanswered; however, MiniMax’s latest announcement shows how advances in generative AI are reshaping creative work while underscoring the importance of continued scientific research, responsible development, and informed public discussion as these tools become more widely adopted.

Source link

July 30, 2026
Repeated Weight Loss and Regain Was Tied to Four Times More Thigh Muscle Loss in a Four-Year MRI Study

People whose weight repeatedly went down and back up over four years lost nearly four times as much thigh muscle as people whose weight stayed steady, and they ended the period weighing about the same as when they started.

That is the central finding of an imaging study of 1,433 middle-aged adults, published in Radiology by a team from the University of California, San Francisco, and described in a UCSF release.

The number that matters: weight cyclers lost about 3.7% of thigh muscle volume over 48 months, compared with about 1% among people whose weight remained relatively stable.

Two clarifications belong immediately. This is an observational study, not a trial, so it shows an association rather than proof that weight cycling caused the muscle loss. And nobody in it was taking a GLP-1 medication, which matters given how the finding is being framed elsewhere.

What the MRI Study Measured

The researchers drew on the Osteoarthritis Initiative, a long-running, NIH-funded cohort of adults at elevated risk for knee osteoarthritis. That is a specific population, not a general sample of American adults.

Participants received MRI scans over four years. Using artificial intelligence to analyze the images, the team measured thigh muscle volume, fat located within the muscle, and fat surrounding the knee. Direct imaging is the methodological advance here, since most weight-cycling research has relied on scales, body-composition estimates, or self-reported dieting history.

The 3.7% versus 1% gap held after the researchers accounted for age, sex, baseline body mass index, physical activity, diet, and other health factors. The published conclusion states that among participants who maintained stable weight over 48 months, “weight cycling was associated with an increased loss of MRI-based thigh muscle volume.”

Notably, the team found no evidence of a difference between groups in the change in intermuscular fat proportion. The signal was in muscle volume, not fat infiltration.

Why the Muscle Did Not Come Back

The detail driving the coverage is directional. Weight came back. Muscle did not.

“When people’s weight cycled, they lost tremendous amounts of muscle along with the fat,” said Thomas Link, MD, PhD, professor of radiology, who led the study with co-first authors Adrian A. Marth, MD, and Gabby Joseph, PhD. He noted the muscle was not regained.

The mechanism is plausible and long suspected. Weight lost through calorie restriction includes lean tissue as well as fat, and regain is more efficiently deposited as fat than as muscle unless resistance training and adequate protein intake are part of the process. Repeat that cycle several times and the composition of a stable-looking body weight shifts.

The illustrative case UCSF released is striking but is a single participant, not a study result: one 62-year-old man’s thigh muscle volume fell 16% over 48 months while his BMI dropped only 1.6%. It shows how invisible this can be on a bathroom scale.

Worth stating carefully: the study followed people for four years. It did not establish that the loss is permanent, only that it had not reversed within that window.

The GLP-1 Question the Study Did Not Answer

This study is being widely presented as a warning about weight-loss drugs. It is not one, and the distinction matters for anyone currently taking these medications.

No participant was on a GLP-1 medication. Link’s own framing was that the insight addresses a question likely to grow in importance as more people start and stop weight-loss therapies, which is a hypothesis about relevance, not a finding about the drugs.

That said, the question is legitimate. People do stop and restart GLP-1s because of cost, coverage changes and side effects, and that pattern resembles weight cycling. MedicalDaily has previously reported on concerns about muscle loss and malnutrition in adults over 65 taking GLP-1 drugs and on the absence of muscle, bone and nutrition screening requirements in the Medicare GLP-1 Bridge program.

What this study adds to that conversation is imaging evidence that repeated cycles compound muscle loss in people not on medication at all. What it does not do is quantify anything about GLP-1 users, and no professional society has issued new guidance in response.

What the Study Cannot Tell You

The limitations are worth holding onto.

It is observational. People who cycle weight may differ from people who do not in ways the adjustments did not capture, including illness, medication use, and eating patterns.

The cohort was middle-aged adults at risk for knee osteoarthritis, a group that may be less mobile and more prone to muscle loss than the general population. The findings may not transfer cleanly to younger or healthier people.

Thigh muscle volume is a reasonable proxy for overall skeletal muscle but is not the same as measured strength, physical function, or fall risk. The study did not report those outcomes.

And four years is the observation window. Longer follow-up would be needed to say anything about permanence.

What to Do With This If You Are Losing Weight

Nobody should stop a prescribed medication because of this study. That includes GLP-1 drugs taken for diabetes or cardiovascular risk, where the consequences of stopping are concrete and immediate.

The reasonable response is to make muscle preservation part of any weight-loss plan rather than an afterthought. That generally means resistance training at least twice weekly and adequate protein intake, and it is worth asking a clinician or a registered dietitian what those targets should be for your age, kidney function and medical history rather than adopting numbers from an article.

People who anticipate a coverage or cost interruption in a weight-loss medication can raise it with a prescriber before it happens, since an unplanned stop and restart is the pattern this research suggests is worth avoiding.

Simple in-office measures of muscle function, including grip strength and a chair-stand test, are available and inexpensive if you want a baseline.

Researchers will need studies that follow people through medication-driven weight loss and regain, with imaging, to answer the question this one raised. That work has not been done.

Frequently Asked Questions

What did the study find? Adults whose weight repeatedly fluctuated over four years lost about 3.7% of thigh muscle volume, compared with about 1% among adults whose weight stayed relatively stable.

Does this prove weight cycling causes muscle loss? No. This was an observational imaging study. It found an association after adjusting for several factors, but it cannot establish cause.

Was the muscle loss permanent? The study found the muscle had not returned within its four-year window. It did not follow participants long enough to establish permanence.

Did the study include people on GLP-1 drugs? No. No participant was taking a weight-loss medication. The connection to GLP-1 use is a question the lead author raised, not something the study measured.

Who was studied? 1,433 middle-aged adults enrolled in the Osteoarthritis Initiative, a cohort of people at elevated risk for knee osteoarthritis. Results may not apply equally to younger or healthier populations.

Should someone stop a weight-loss medication because of this? No. Do not stop or change a prescribed medication based on a news report. Discuss any concerns with the prescribing clinician.

How can someone protect muscle during weight loss? Resistance training and adequate protein intake are the established approaches. Specific targets should come from a clinician or registered dietitian, not from an article.

Source link

July 29, 2026